Gilead Sciences are expected to show Q1 profits of $0.89 per share on revenue of $3.92bn. The company will be looking to convince investors that the political pressure on drug pricing from the company's hepatitis C drug Sovaldi is not impacting earnings. The likelihood is that earnings to date will be good, but probably more important for the stock price going forward will be any guidance on the future pricing structure of Sovaldi and other product lines. Without assurance that companies in the sector can continue to charge similar prices, biotech may well remain under pressure despite beating earnings expectations.


Disclaimer: CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.